

0570  
-10

45 OIPE

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/874,141

DATE: 11/28/2001

TIME: 10:27:19

Input Set : A:\37003632.app

Output Set: N:\CRF3\11212001\I874141.raw

ENTERED

```

3 <110> APPLICANT: ANDERSON, DARRELL
4     PAN, LI-ZHEN
5     HANNA, NABIL
6     RASTETTER, WILLIAM H.
7     KLOETZER, WILLIAM S.
9 <120> TITLE OF INVENTION: NON-AGONISTIC ANTIBODIES TO HUMAN GP39, COMPOSITIONS
10    CONTAINING, AND THERAPEUTIC USE THEREOF
12 <130> FILE REFERENCE: 037003-0280632
14 <140> CURRENT APPLICATION NUMBER: 09/874,141
15 <141> CURRENT FILING DATE: 2001-06-06
17 <150> PRIOR APPLICATION NUMBER: 60/209,584
18 <151> PRIOR FILING DATE: 2000-06-06
20 <160> NUMBER OF SEQ ID NOS: 53
22 <170> SOFTWARE: PatentIn Ver. 2.1
24 <210> SEQ ID NO: 1
25 <211> LENGTH: 107
26 <212> TYPE: PRT
27 <213> ORGANISM: Artificial Sequence
29 <220> FEATURE:
30 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
31    humanized peptide
33 <400> SEQUENCE: 1
34 Asp Ile Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly
35 1             5             10             15
37 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Ile Thr Ala
38             20             25             30
40 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro Lys Leu Leu Ile
41             35             40             45
43 Tyr Ser Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Ser Gly
44             50             55             60
46 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
47 65             70             75             80
49 Glu Asp Phe Ala Asp Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Tyr
50             85             90             95
52 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
53             100             105
56 <210> SEQ ID NO: 2
57 <211> LENGTH: 107
58 <212> TYPE: PRT
59 <213> ORGANISM: Artificial Sequence
61 <220> FEATURE:
62 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
63    humanized peptide
65 <400> SEQUENCE: 2
66 Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
67 1             5             10             15
69 Glu Arg Ala Thr Ile Asn Cys Lys Ala Ser Gln Asn Val Ile Thr Ala

```

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/874,141

DATE: 11/28/2001

TIME: 10:27:19

Input Set : A:\37003632.app

Output Set: N:\CRF3\11212001\I874141.raw

```

70          20          25          30
72 Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
73          35          40          45
75 Tyr Ser Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Ser Gly
76          50          55          60
78 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
79 65          70          75          80
81 Glu Asp Val Ala Asp Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Tyr
82          85          90          95
84 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
85          100          105
88 <210> SEQ ID NO: 3
89 <211> LENGTH: 107
90 <212> TYPE: PRT
91 <213> ORGANISM: Artificial Sequence
93 <220> FEATURE:
94 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
95     humanized peptide
97 <400> SEQUENCE: 3
98 Asp Ile Val Met Thr Gln Ser Pro Ser Phe Met Ser Thr Ser Val Gly
99 1          5          10          15
101 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Ile Thr Ala
102          20          25          30
104 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro Lys Leu Leu Ile
105          35          40          45
107 Tyr Ser Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Ser Gly
108          50          55          60
110 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Met Gln Pro
111 65          70          75          80
113 Glu Asp Phe Ala Asp Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Tyr
114          85          90          95
116 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
117          100          105
120 <210> SEQ ID NO: 4
121 <211> LENGTH: 107
122 <212> TYPE: PRT
123 <213> ORGANISM: Artificial Sequence
125 <220> FEATURE:
126 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
127     humanized peptide
129 <400> SEQUENCE: 4
130 Asp Ile Val Met Thr Gln Ser Pro Asp Ser Met Ala Thr Ser Leu Gly
131 1          5          10          15
133 Glu Arg Val Thr Ile Asn Cys Lys Ala Ser Gln Asn Val Ile Thr Ala
134          20          25          30
136 Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
137          35          40          45
139 Tyr Ser Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Ser Gly
140          50          55          60

```

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/874,141

DATE: 11/28/2001

TIME: 10:27:19

Input Set : A:\37003632.app

Output Set: N:\CRF3\11212001\I874141.raw

```

142 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Met Gln Ala
143 65 70 75 80
145 Glu Asp Val Ala Asp Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Tyr
146 85 90 95
148 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
149 100 105
152 <210> SEQ ID NO: 5
153 <211> LENGTH: 120
154 <212> TYPE: PRT
155 <213> ORGANISM: Artificial Sequence
157 <220> FEATURE:
158 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
159 humanized peptide
161 <400> SEQUENCE: 5
162 Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
163 1 5 10 15
165 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Thr Asn Gly
166 20 25 30
168 Phe Trp Ile Trp Ile Arg Lys Pro Pro Gly Asn Lys Leu Glu Tyr Met
169 35 40 45
171 Gly Tyr Ile Ser Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys
172 50 55 60
174 Ser Arg Ile Ser Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Ser Leu
175 65 70 75 80
177 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Gly Val Tyr Tyr Cys Ala
178 85 90 95
180 Cys Arg Ser Tyr Gly Arg Thr Pro Tyr Tyr Phe Asp Phe Trp Gly Gln
181 100 105 110
183 Gly Thr Thr Leu Thr Val Ser Ser
184 115 120
187 <210> SEQ ID NO: 6
188 <211> LENGTH: 120
189 <212> TYPE: PRT
190 <213> ORGANISM: Artificial Sequence
192 <220> FEATURE:
193 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
194 humanized peptide
196 <400> SEQUENCE: 6
197 Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
198 1 5 10 15
200 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Thr Asn Gly
201 20 25 30
203 Phe Trp Ile Trp Ile Arg Lys His Pro Gly Asn Lys Leu Glu Tyr Met
204 35 40 45
206 Gly Tyr Ile Ser Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys
207 50 55 60
209 Ser Arg Ile Ser Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Ser Leu
210 65 70 75 80
212 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Gly Val Tyr Tyr Cys Ala

```

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/874,141

DATE: 11/28/2001

TIME: 10:27:19

Input Set : A:\37003632.app

Output Set: N:\CRF3\11212001\I874141.raw

```

213              85              90              95
215 Cys Arg Ser Tyr Gly Arg Thr Pro Tyr Tyr Phe Asp Phe Trp Gly Gln
216              100              105              110
218 Gly Thr Thr Leu Thr Val Ser Ser
219              115              120
222 <210> SEQ ID NO: 7
223 <211> LENGTH: 120
224 <212> TYPE: PRT
225 <213> ORGANISM: Artificial Sequence
227 <220> FEATURE:
228 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
229      humanized peptide
231 <400> SEQUENCE: 7
232 Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
233 1              5              10              15
235 Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Asp Ser Ile Thr Asn Gly
236              20              25              30
238 Phe Trp Ile Trp Ile Arg Lys His Pro Gly Asn Lys Leu Glu Tyr Met
239              35              40              45
241 Gly Tyr Ile Ser Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys
242              50              55              60
244 Ser Arg Ile Ser Ile Ser Arg Asp Thr Ser Asn Asn Gln Phe Ser Leu
245 65              70              75              80
247 Asn Leu Asn Ser Val Thr Arg Ala Asp Thr Gly Val Tyr Tyr Cys Ala
248              85              90              95
250 Cys Arg Ser Tyr Gly Arg Thr Pro Tyr Tyr Phe Asp Phe Trp Gly Gln
251              100              105              110
253 Gly Thr Thr Leu Thr Val Ser Ser
254              115              120
257 <210> SEQ ID NO: 8
258 <211> LENGTH: 120
259 <212> TYPE: PRT
260 <213> ORGANISM: Artificial Sequence
262 <220> FEATURE:
263 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
264      humanized peptide
266 <400> SEQUENCE: 8
267 Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
268 1              5              10              15
270 Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Asp Ser Ile Thr Asn Gly
271              20              25              30
273 Phe Trp Ile Trp Ile Arg Lys Pro Pro Gly Asn Lys Leu Glu Tyr Met
274              35              40              45
276 Gly Tyr Ile Ser Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys
277              50              55              60
279 Ser Arg Ile Ser Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Tyr Leu
280 65              70              75              80
282 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Gly Val Tyr Tyr Cys Ala
283              85              90              95

```

## RAW SEQUENCE LISTING

DATE: 11/28/2001

PATENT APPLICATION: US/09/874,141

TIME: 10:27:19

Input Set : A:\37003632.app

Output Set: N:\CRF3\11212001\I874141.raw

```

285 Cys Arg Ser Tyr Gly Arg Thr Pro Tyr Tyr Phe Asp Phe Trp Gly Gln
286           100                      105                      110
288 Gly Thr Thr Leu Thr Val Ser Ser
289           115                      120
292 <210> SEQ ID NO: 9
293 <211> LENGTH: 107
294 <212> TYPE: PRT
295 <213> ORGANISM: Artificial Sequence
297 <220> FEATURE:
298 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
299     humanized peptide
301 <400> SEQUENCE: 9
302 Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly
303   1           5                      10                      15
305 Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Ile Thr Ala
306           20                      25                      30
308 Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
309           35                      40                      45
311 Tyr Ser Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Ser Gly
312           50                      55                      60
314 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Met Gln Ser
315   65           70                      75                      80
317 Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Tyr
318           85                      90                      95
320 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
321           100                      105
324 <210> SEQ ID NO: 10
325 <211> LENGTH: 120
326 <212> TYPE: PRT
327 <213> ORGANISM: Artificial Sequence
329 <220> FEATURE:
330 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
331     humanized peptide
333 <400> SEQUENCE: 10
334 Glu Val Gln Leu Gln Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln
335   1           5                      10                      15
337 Thr Leu Ser Leu Thr Cys Ser Val Thr Gly Asp Ser Ile Thr Asn Gly
338           20                      25                      30
340 Phe Trp Ile Trp Ile Arg Lys Phe Pro Gly Asn Lys Leu Glu Tyr Met
341           35                      40                      45
343 Gly Tyr Ile Ser Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys
344           50                      55                      60
346 Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Gln Asn Gln Phe Tyr Leu
347   65           70                      75                      80
349 Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Gly Thr Tyr Tyr Cys Ala
350           85                      90                      95
352 Cys Arg Ser Tyr Gly Arg Thr Pro Tyr Tyr Phe Asp Phe Trp Gly Gln
353           100                      105                      110
355 Gly Thr Thr Leu Thr Val Ser Ser

```

**VERIFICATION SUMMARY**

PATENT APPLICATION: US/09/874,141

DATE: 11/28/2001

TIME: 10:27:20

Input Set : A:\37003632.app

Output Set: N:\CRF3\11212001\I874141.raw